AVLN Stock Analysis: Avalyn Pharma Common Stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.318m USD | 12M Return: -4.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.6M
Warnings
Tailwinds
No distinct edge detected
Seasonality 0.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Avalyn Pharma Inc. (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, developing inhaled medicines for rare respiratory diseases, with a primary focus on pulmonary fibrosis and other interstitial lung diseases. The company was incorporated in 2011, originally as Genoa Pharmaceuticals, Inc., before adopting its current name in July 2017.
The companys pipeline centers on inhaled reformulations of two established oral antifibrotics, pirfenidone and nintedanib, which are the current standard-of-care treatments for idiopathic pulmonary fibrosis (IPF). Lead candidates include AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib) for progressive pulmonary fibrosis and IPF, as well as AP03, a fixed-dose combination delivering both agents simultaneously to provide dual antifibrotic activity through direct lung delivery.
As a clinical-stage biotech, Avalyn is pre-revenue and depends on capital markets to fund development, targeting an area of high unmet need where treatment is limited to a small patient population. Its inhaled delivery approach is intended to maximize lung exposure while potentially limiting the systemic side effects commonly associated with the oral versions of these drugs.
- AP01 Phase 2 results in pulmonary fibrosis expected
- Clinical trial cash burn heightens share dilution risk
- Inhaled formulations challenge oral nintedanib and pirfenidone market
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.60 > 0.02 and ΔFCF/TA -21.40 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.60 > 3% & CFO -81.5m > Net Income -85.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.03 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (41.8m) vs prev 0.0% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 130.0m - Total Current Liabilities 11.8m) / Total Assets 135.7m |
| B: -2.15 (Retained Earnings -292.2m / Total Assets 135.7m) |
| C: -0.70 (EBIT TTM -91.3m / Avg Total Assets 130.1m) |
| D: -0.66 (Book Value of Equity -264.2m / Total Liabilities 399.9m) |
| Altman-Z'' = -6.72 = D |
As of July 08, 2026, the stock is trading at USD 28.42 with a total of 395,639 shares traded. Over the past week, the price has changed by -8.32%, over one month by +1.28%, over three months by -4.76% and over the past year by -4.76%.
Current recommended Stop Loss: 23.60 (which is 17% or 1.7 ATR below the current price).
Avalyn Pharma Common Stock has no consensus analysts rating.
P/B = 11.7139
Revenue TTM = 0.0 USD
EBIT TTM = -91.3m USD
EBITDA TTM = -91.2m USD
Long Term Debt = 14.8m USD (from longTermDebt, last quarter)
Short Term Debt = 507k USD (from shortTermDebt, last quarter)
Debt = 18.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.60m
Net Debt = -105.1m USD (calculated: Debt 18.0m - CCE 123.1m)
Enterprise Value = 1.21b USD (1.32b + Debt 18.0m - CCE 123.1m)
Interest Coverage Ratio = unknown (Ebit TTM -91.3m / Interest Expense TTM 0.0)
EV/FCF = -14.82x (Enterprise Value 1.21b / FCF TTM -81.8m)
FCF Yield = -6.75% (FCF TTM -81.8m / Enterprise Value 1.21b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 8.94 (Enterprise Value 1.21b / Total Assets 135.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 18.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -72.1m (EBIT -91.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.70 (Total Current Assets 130.0m / Total Current Liabilities 14.9m)
Debt / Equity = -0.07 (negative equity) (Debt 18.0m / totalStockholderEquity, last quarter -264.2m)
Debt / EBITDA = 1.15 (negative EBITDA) (Net Debt -105.1m / EBITDA -91.2m)
Debt / FCF = 1.28 (negative FCF - burning cash) (Net Debt -105.1m / FCF TTM -81.8m)
Total Stockholder Equity = -238.7m (last fiscal year from totalStockholderEquity)
RoA = -65.50% (Net Income -85.2m / Total Assets 135.7m)
RoE = 35.70% (negative equity) (Net Income TTM -85.2m / Total Stockholder Equity -238.7m)
RoCE = 40.78% (negative capital employed) (EBIT -91.3m / Capital Employed (Equity -238.7m + L.T.Debt 14.8m))
RoIC = -57.98% (negative operating profit) (NOPAT -72.1m / Invested Capital 124.4m)
WACC = 0.0% (E(1.32b)/V(1.34b) * Re(0.0%) + D(18.0m)/V(1.34b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.29% (= Risk Free + ERP)
[DCF] Fair Price = unknown (Cash Flow -81.8m)
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.56 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.58 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.94 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.90 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+2.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=0, down=0)